Cervical screening programmes are moving towards HPV testing as part of the screening process and as a triage for colposcopy. Three HPV detection methods were evaluated using cervical cytology specimens from colposcopy patients. PreservCyt™ liquid based cytology specimens from 241 women attending colposcopy clinics with greater than 2 persistently abnormal smears were recruited through the Coombe Women and Infants University Hospital, Dublin. HPV DNA was detected by Hybrid Capture (HC2) for 13 high-risk HPV types, Full-Spectrum HPV (FS-HPV) for 49 high and low-risk types and Molecular Beacon Real-Time HPV assay (MBRT-HPV) for 16 high and low-risk types. 
Introduction
Cervical screening programmes worldwide are moving towards HPV DNA testing as part of the screening process as either a co-test alongside cytology (Naucler et al., 2009; Castle et al., 2010) , in primary screening or in triage of women with Low-Grade Squamous Intraepithelial Lesions or Atypical Squamous Cells of Undetermined Significance (Castle et al., 2010; Ronco et al., 2007; ALTS Group, 2003) , in particular for women over the age of 30-35 years and as a test of cure for post treatment disease surveillance (Kreimer et al., 2006; Kreimer et al., 2007) . As a consequence of the increased utility of HPV DNA testing, many new HPV DNA tests are becoming rapidly available, and existing HPV tests are evolving constantly to meet the needs of the end-user. At least 125 distinct HPV tests have been identified, with 84 variants of the same and for more than 75% of the HPV tests currently on the market, there is no single reference publication in the peer-reviewed literature (Poljak et al., 2012) . The most commonly used commercially available HPV DNA tests include Hybrid Capture 2 for high-risk HPV (HC2), (Qiagen, Hilden, Germany) , (Giorgi-Rossi et al., 2011) , HC2 for detection of HPV 16, HPV 18 and HPV 45 (Qiagen, Hilden, Germany), (Thai et al., 2009) , the Cervista™ HR HPV test (Hologic, Bedford, MA, USA), (Youens et al., 2011) , the Cervista™ HPV 16, HPV 18 test (Hologic, Bedford, MA, USA), (Einstein et al., 2011) , the Cobas 4800 HPV test (Roche Diagnostics, Mannheim, Germany), (Stoler et al., 2011) , Papillocheck (Greiner Bio-One, Frickenhausen, Germany), (Dalstein et al., 2009) , the Full-Spectrum HPV Amplification and Detection System (GenoID, Budapest, Hungary), (Jeney et al., 2007) , GenoID Real-Time HPV Assay (GenoID, Budapest, Hungary), (Takacs et al., 2008) and the Linear Array HPV Genotyping Test (Roche Diagnostics, Mannheim, Germany), (Dobec et al., 2011) , to name but a few. The HC2 test and the Cervista test received FDA approval in 2003 and 2009 respectively, for triage of women with equivocal cytology graded as Atypical Squamous Cells of Undetermined Significance and for use in women 30+ years of age in addition to routine cytology screening. Cobas 4800 HPV test, which tests for high-risk HPV and genotypes concurrently for HPV 16/18, received FDA approval in 2011 for use as an adjunct test to cytology in women >30 years of age, in women 21 years or older with Atypical Squamous Cells of Undetermined Significance and in women 21 years and older for the assessment of the presence of HPV genotypes 16 or 18 (Poljak et al., 2012) . Each of these HPV tests uses a different quantity of starting specimen, uses different chemistry and gives different information on high-risk HPV infection, depending on the assay format. Thus, it is necessary to assess the performance of a given HPV assay in its intended test setting and on the study population for which it is intended before it can be used clinically.
Recent guidelines developed for primary screening in women >30 years and for the evaluation of new HPV tests have recommended that the performance of all HPV assays is assessed relative to HC2 and that in a triage setting HPV DNA tests should be evaluated in combination with adjunctive biomarker tests (eg. viral E6/E7, genotyping, p16 immunostaining or promoter methylation status) and compared M a n u s c r i p t to histological outcome to aid risk stratification of HPV positive women with normal cytology or identify women with higher grades of cytology who will only ever develop a lesion that is minimally invasive (Meijer et al., 2009 ). It has also been suggested that in a colposcopy setting, in order to achieve a balance between sensitivity and specificity, HPV testing should be evaluated in terms of target assayed, age of the women who are tested and the assay cut-off for a positive result (Cuschieri et al., 2014) In this study, the performance of three commercially available HPV DNA tests were compared in a colposcopy referred cohort of women: HC2 for detection of 13 high-risk HPV types, Full-Spectrum HPV (FS-HPV) for 49 high and low-risk types and Molecular Beacon Real-Time HPV assay (MBRT-HPV) for 16 high and low-risk types. The FS-HPV test is a PCR based assay for the HPV L1 gene, followed by an ELISA based 96 well hybridisation assay to a cocktail of probes for the detection of either high-risk HPV, low-risk HPV or a panel of HPV genotypes whose risk is not yet determined (Jeney et al., 2007) . The MBRT-HPV assay is a molecular beacon real-time multiplex PCR assay that detects HPV using combined probes as either HPV 16 or HPV 18, one of a panel of 12 high-risk HPV types or as low-risk HPV (HPV 6 or HPV 11), (Takacs et al., 2008) . While both of these assays carry the CE-IVD approval mark, few studies are available which compare the performance of the FS-HPV or the MBRT-HPV, (Jeney et al., 2007 and Takacs et al., 2008) . HPV genotyping was performed on all specimens using the Linear Array HPV Genotyping Test (LA-HPV), for 37 ano-genital HPV types, to determine if the performance difference of a particular HPV DNA test is attributable to a) HPV genotypes present in this population that are included in one HPV test but not the others, b) HPV genotypes that are detected at different levels of sensitivity by each of the tests c) HPV genotypes that are outside the screening range of the HPV DNA tests chosen for analysis of this colposcopy study population.
The objective of this study was to compare the performance of the HC2 test, the FS-HPV and the MBRT-HPV assay in the Irish colposcopy setting. Non-concordant results were discriminated using the LA-HPV and a "HPV genotype snapshot" of the women attending colposcopy at Coombe Women and Infants University Hospital, prior to the introduction of HPV DNA testing was taken. This is the first time that a full HPV genotyping analysis of women attending colposcopy clinics of Coombe Women and Infants University Hospital has been performed. M a n u s c r i p t
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Materials and methods 
Patient recruitment and clinical specimens

Hybrid capture HR-HPV DNA detection
DNA was extracted from an aliquot of 4mL PreservCyt™ specimen using the Sample Conversion Kit (Qiagen, Hilden, Germany) for high-risk HPV testing by Hybrid Capture (HC2; Qiagen, Hilden Germany). The HPV DNA status of the specimens was assessed using the HC2 HPV kit for high-risk HPV detection of types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68, according 7, 10, 13, 26, 27, 28, 29, 30, 34, 40, 53, 54, 57, 61, 67, 70, 72, 73, 74, 81, 82, 83, 84, 85, 89, 90 and 91.
Molecular beacon based real-time HPV detection
The MBRT-HPV is a real-time molecular beacon based multiplex assay performed in a multiwell plate. It has the ability to distinguish HPV positivity as HPV 16 or 18 using a 5'-JOE labelled molecular beacon, as high-risk HPV positive for one or more of 12 HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 ) using a 5'-TET labelled molecular beacon or as low-risk positive for HPV types 6 and/or 11, using a 5'-Texas-Red-(T) 6-FAM (wavelength shifted) labelled molecular beacon, while the internal control is detected by a 5'-FAM labelled molecular beacon. These four reactions occur in the one well with all the primers and probes contained in the MBRT-HPV mastermix (GenoID, Budapest, Hungary). The MBRT-HPV assay was performed on a second aliquot of the extracted nucleic acid according to manufacturer's instructions. Briefly, 3.5uL of nucleic acid was added to MBRT-HPV mastermix containing a final volume of 11uL per reaction and cycling was performed on an AB7900 (Life Technologies, Carlsbad, CA, USA) with thermo-cycling conditions as follows: 95˚C for 10 min, 55˚C for 5 min, (95˚C 15 s, 30˚C 20s, 95˚C 15s, 50˚C for 1 min) x25.
Results were interpreted according to the manufacturer's instructions.
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HPV genotyping using Linear Array HPV Test
Nucleic acids were extracted from 250uL of PreservCyt™ for the Linear Array HPV genotyping assay using the Amplilute® Liquid Media Extraction kit, (Roche, Mannheim, Germany) as described by the manufacturer's instructions. Briefly, PCR amplification and line blot colorimetric detection were performed for HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84 , IS39 and CP6108.
Statistical analysis
Proportional agreement between tests was assessed using Cohen's Kappa (k) and a McNemar's Test was used to assess statistical significance. Sensitivity and positive predictive values were assessed using histology confirmed Cervical Intraepithelial Neoplasia Grade 2+ as the gold standard and the 0.95 confidence interval.
Results
Cytological and histological characteristics of the study patients
In total, 14.5% (35/241) of cytology specimens were diagnosed as Negative for Intraepithelial Lesions A c c e p t e d M a n u s c r i p t
HPV prevalence
PreservCyt specimens (N=241) were tested for HPV prevalence by each of the three assays: HC2, Full-Spectrum HPV (FS-HPV) and Molecular Beacon Based Real-Time HPV assay (MBRT-HPV). 
HPV prevalence across cytological categories
The overall prevalence of HPV in each of the cytological categories is presented in A c c e p t e d M a n u s c r i p t (9.1%), HPV 61 (7.9%), HPV 53 (7.9%), HPV 18 (6.6%), HPV 62 (6.6%) and HPV 45 (6.6%), ( Multiple HPV genotypes were detected in 138/239 (57.7%) of all specimens.
Sensitivity and positive predictive value of HPV tests
HPV genotype and cytology distribution
HPV 16 was the most common HPV genotype across all cytological disease categories ( (Figure 1 ).
HPV genotype and histology status
In cytology specimens with a matched histology specimen which was Cervical Intraepithelial Neoplasia Grade 2+, HPV 16 (66.4%) was the most prevalent followed by HPV 31 (22.1%), HPV 33 (18.32%), HPV 58 (9.2%), HPV 62 (8.4%), HPV 45 (7.6%), HPV 18 (6.1%), HPV 51 (6.1%), HPV 59 (6.1%) and HPV 39 (4.6%). The most commonly detected low-risk HPV genotype in this cohort was HPV 42 (7.6%). HPV 42 was the 6 th most commonly detected genotype overall in this study. The multiple infection rate in this cohort was 58.8%.
HPV genotyping to resolve discrepant HPV detection results
HPV genotyping was performed to evaluate specimens with a discrepant result for high-risk HPV using the other 3 technologies i.e. specimens that were concordant by 2 or more of either FS-HPV (high-risk), MBRT-HPV (16/18 or high-risk), HC2 or LA-HPV genotyping test for high-risk HPV (Supplemental Table 2 ). Where a sample was positive by 2 tests and one of those was the LA-HPV genotyping assay, the genotype assigned to that specimen was the LA-HPV result. A negative LA-HPV result was used to determine a false positive HPV detection result in situations where a cytology specimen was positive for HPV by one technology only but was negative by LA-HPV for any of the HPV genotypes tested by that technology. A cytology specimen had a false negative result for a particular technology, if it was positive by the other two HPV detection technologies or by one technology and was positive by LA-HPV for one or more of the genotypes detected by that technology.
As no one test was 100% sensitive, there were false positive HPV results and false negative HPV results using each test method. The HC2 high-risk HPV, which screens for 13 high-risk HPV genotypes, gave 4 false positive high-risk HPV and 4 false negative high-risk HPV in this population, when compared to LA-HPV, FS-HPV assay, and MBRT-HPV. Two of the 4 false positives were M a n u s c r i p t falsely positive due to cross reaction with low-risk HPV types and the remaining two were HPV negative by all other assays. The 4 HC2 false negative samples contained high-risk HPV genotypes 16, 39, 56, 51 and 52 and were positive by either the FS-HPV or the MBRT-HPV for high-risk HPV.
Three of the four samples contained HPV 16.
For the MBRT-HPV, which screens for 14 high-risk HPV and 2 low-risk, 16 false negatives and 3 false positives were detected. The 16 false negatives contained a mixture of high-risk HPV genotypes 35, 52, 16, 68, 39, 51, 56, 31, 58 . The high-risk HPV genotypes that occurred most frequently in specimens that were false negative by MBRT-HPV were HPV 16 (9/16) and HPV 51 (4/16). M a n u s c r i p t
Discussion
This study compared the performance of three commercially available HPV detection methods (HC2, FS-HPV and MBRT-HPV), in cervical cytology specimens of women attending the colposcopy clinics of Coombe Women and Infants University Hospital, Dublin. The infecting HPV genotypes in these women were identified by LA-HPV. This is the first study which examines the performance of the FS-HPV and the MBRT-HPV for HPV detection in colposcopy patients and is the first review of HPV genotypes in an Irish colposcopy setting.
No HPV assay detected 100% of HPV infections, and there were false positive and false negative HPV results by each of the assays (Supplemental Table 2 ), by comparison to the other tests. As expected in this cohort of women with persistently abnormal cervical cytology smears, the prevalence of HPV was high by each of the assays at 83.3% for HC2, 91.9% for FS-HPV and 80.1% for MBRT-HPV, with adjusted high-risk only HPV detection rates of 61.4% for FS-HPV and 78.7% for MBRT-HPV (Table 1) . Other studies which have examined prevalence of high-risk HPV infections in mixed colposcopy referral populations have noted high HPV prevalence rates regardless of the HPV DNA detection assay used (Cuschieri et al, 2014; Szarewski et al., 2012) , indicating that most commercially available assays are sufficiently sensitive for HPV detection in this setting. The HC2 test and the FS-HPV had similar HPV detection rates across all grades of cytology whereas the MBRT-HPV had a much lower rate, which was probably associated with its lower analytical sensitivity for HPV 16, combined with the fact that HPV 16 was the most dominant HPV genotype overall. It has been suggested that the performance of HPV assays in a triage setting should be assessed with relevance to age among other factors (Cuschieri et al, 2014) . Reflecting the natural history of HPV infections, Low-Grade Squamous Intraepithelial Lesions were associated with younger age (<30 years) while High-Grade Squamous Intraepithelial Lesions were statistically more common in women 30+ years of age. In this study, high-risk HPV DNA prevalence was highest for each assay in women under 30 years of age, indicating that a second triage test in addition to HPV DNA in younger women may be necessary for further risk stratification.
The GenoID FS-HPV assay and the MBRT-HPV were first described in 2007 and 2008, and while they are CE marked they are mainly only in use throughout Hungary thus far. More studies such as this one are warranted to assess the performance of these two assays in different test settings and in different populations. In a previous publication, FS-HPV was compared to HC2 for detection of HPV in 81 women with Atypical Squamous Cells of Undetermined Significance or Squamous
Intraepithelial Lesions giving a concordance rate of 83.9%, which compares well to this study where concordance was 93.7% in the same cytological category (Jeney et al., 2007) . In the study which first describes the MBRT-HPV assay, its concordance to FS-HPV for detection of HPV was 89.44% (Takacs et al., 2008) , comparing well to this study (83.8%). Meijer et al., have suggested that new M a n u s c r i p t HPV screening tests are assessed relative to HC2 (Meijer et al., 2009) . When compared to HC2, the FS-HPV showed greater concordance (94.6% (k=0.792)) than the MBRT-HPV (87.4% (k=0.532)) for detection of high-risk HPV types and there was no statistical difference between the HC2 test and the FS-HPV for the detection of high-risk HPV overall.
The HC2 assay was the most sensitive for high-risk HPV detection in Cervical Intraepithelial
Neoplasia Grade 2+ disease (98.3%), followed closely by the FS-HPV ( Grade 2+ was 96% (Mesher et al., 2013) . In a European retrospective study by Denton et al, HC2 had a sensitivity of 90.1% for the identification of biopsy confirmed high-grade Cervical Intraepithelial
Neoplasia at 6 months in women presenting with Atypical Squamous Cells of Undetermined Significance cytology and 95.7% in women with Low-Grade Squamous Intraepithelial Lesions (Denton et al., 2010) . In a previous study performed in a colposcopy referred population in another Dublin maternity hospital, HC2 had a sensitivity of 90.5% for detection of CIN2+, which is slightly lower than reported in this study, however that study was of women referred for persistently lowgrade cytology only and unlike this study there were no women who had high-grade cytology (White et al., 2013) .
The LA-HPV assay was used in this study to provide a snapshot of the HPV genotypes present in a colposcopy referred cohort of women and to assess whether the HPV genotype coverage of each of the detection assays affected their clinical performance. Only for the MBRT-HPV assay did the genotyping analysis reveal reduced positivity that could be attributed to failed detection of a particular HPV genotype (HPV 16) which was included in the assay. The MBRT-HPV test has a lower M a n u s c r i p t analytical sensitivity than the other tests for HPV 16 which is demonstrated by a lower clinical sensitivity than either the HC2 or the FS-HPV tests (Table 2) . (Tjalma et al., 2013) .
In this study, 4 of the 10 HPV genotypes detected most commonly were low-risk. Analysis of HPV genotypes across the cytology categories showed that low-risk HPV genotypes were identified in all While not explored in this study, the FS-HPV test can also be used to identify specific HPV genotypes using type specific HPV hybridization probes rather than pooled HPV probes following amplification of a general HPV amplicon using the L1F/L1R primer set (Jeney et al., 2007) . Such type specific identification alongside the general detection of HPVs whose risk classification is not yet known using the "HPV with unclassified risk" probe set, may permit interrogation of a sample for specific recurrent HPV genotypes while monitoring for a shift in the prevalence of certain HPV genotypes following the introduction of HPV vaccination programmes. The extended coverage of the FS-HPV assay may be useful for detection of HPV genotypes other than the high-risk genital types which may be associated with dermatological conditions, head and neck cancers or it may be useful to a laboratory that wishes to extend HPV testing outside of the genital space.
Multiple infections were a common feature, with 58% of women having greater than one genotype.
The multiple infection rate of this colposcopy referred population was very similar to that of our routine screening population (56.5%, unpublished results). In this study, multiple infections were highest in cytology specimens of the Low-Grade Squamous Intraepithelial Lesions cytology group (Wentzensen et al., 2012) . The propensity of intermittent infections and low viral load infections to cause cytological changes remains unclear and it has been shown repeatedly that persistently testing positive for any high-risk HPV genotype is a good surrogate for HPV genotype specific persistence, particularly in women aged 30 years and older ). However, despite advances in HPV detection technologies and a move towards grouped HPV detection of selected high-risk HPV genotypes, there is no convenient way to identify type specific persistence other than by multiple screening rounds using type specific methods that are often very labour intensive and are performed manually.
Overall, this study describes comparable performance of the HC2 and the FS-HPV assay in colposcopy patients and provides a useful snapshot of the HPV genotypes present before commencement of HPV testing as triage, or as test of cure. While the MBRT-HPV assay is slightly less sensitive than either the HC2 or the FS-HPV, it has a higher positive predictive value and as it is a real-time PCR based technology it can be readily automated. As the FS-HPV PCR amplicon can be readily genotyped, HPV testing using the FS-HPV may be a useful alternative to the HC2 in populations which require HPV genotyping or where the prevalence of a particular genotype needs monitoring. Preliminary studies, to compare the performance of different HPV detection assays and assess the HPV genotype distribution in a given population, are warranted, prior to selecting a HPV assay for use in cervical screening.
M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t (16,18,31,33,35,39,45,51,56,58,59,66 and 68) and 21 HPV genotypes of either low or undetermined risk in a colposcopy cohort of 239 women.
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